Butyrate ameliorates antibiotic-driven type 1 diabetes in the female offspring of non-obese diabetic mice. - GreenMedInfo Summary
Butyrate Ameliorates Antibiotic-driven Type 1 Diabetes in the Female Offspring of Non-Obese Diabetic Mice.
J Agric Food Chem. 2020 Feb 12. Epub 2020 Feb 12. PMID: 32046486
Lingling Jia
Maternal gut dysbiosis affects the development of offspring immune system. Our previous study has indicated that microbial metabolite butyrate directly shapes pancreatic immune tolerance and dampens type 1 diabetes (T1D) progression. Therefore, maternal butyrate intervention may protect their offspring from maternal gut dysbiosis-accelerated T1D. To test this, pregnant non-obese diabetic (NOD) mice were treated with vancomycin in drinking water with or without a butyrate-supplemented diet during gestation and nursing (oral vancomycin is used to induce maternal gut dysbiosis). Three weeks after delivery, T1D-associated innate and adaptive immune cells were detected to investigate the effects of butyrate on the vancomycin-exacerbated pancreatic immune disorder in dams and pups. The results showed that butyrate inhibited maternal vancomycin-exacerbated secretion of pro-inflammation cytokines (interferonγ and interleukin 1β) and maternal vancomycin-exacerbated recruitment of interferon γ+ T cells (cytotoxic T lymphocytes 1 cells and T helper type 1 cells) in the pancreas of the female offspring, thus dampening T1D development. The protection may be due to butyrate inhibiting the activation of pancreatic dendritic cells (DCs). Our data thus demonstrate that maternal gut dysbiosis can exacerbate pancreatic-directed autoimmunity in the female offspring through T cell- and DCs-associated mechanisms that are inhibited by butyrate.